Company intelligence / Profile preview

Progenitec

Ownership: Private
Development stage: Preclinical

Overview

Progenitec is developing innovative diagnostic devices to detect non-healing and infected chronic wounds by analyzing discarded wound dressings. Their two main products, DETEC® pH and DETEC® Esterase, are designed to provide objective biomarkers for wound healing status and infection risk. The company has secured over $3 million in NIH funding in the past five years and is currently working toward FDA clearance[1].

Therapeutic areas: DermatologyInfectious Diseases
Modalities: Device
Industry: Protein Biomarker Diagnostics

Beyond the preview

Go deeper on Progenitec.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Progenitec.

Explore the full profile